$-0.14 EPS Expected for Cytosorbents (CTSO); Borgwarner (BWA) Sentiment Is 1.13

BorgWarner Inc. (NYSE:BWA) Logo

Analysts expect Cytosorbents Corporation (NASDAQ:CTSO) to report $-0.14 EPS on November, 5.They anticipate $0.04 EPS change or 40.00% from last quarter’s $-0.1 EPS. After having $-0.11 EPS previously, Cytosorbents Corporation’s analysts see 27.27% EPS growth. The stock decreased 7.36% or $0.37 during the last trading session, reaching $4.66. About 153,862 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 40.00% since October 1, 2018 and is downtrending. It has underperformed by 40.00% the S&P500. Some Historical CTSO News: 08/05/2018 - CYTOSORBENTS CORP - QTRLY SHR LOSS $0.10; 22/05/2018 - CytoSorbents Presenting at Conference Tomorrow; 09/04/2018 - CytoSorbents Presenting at Conference Apr 9; 17/05/2018 - CYTOSORBENTS CORP CTSO.O : COWEN AND COMPANY RAISES TARGET PRICE TO $11 FROM $9; 09/04/2018 - CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich; 14/05/2018 - CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use; 04/04/2018 - CYTOSORBENTS CORP - INTENDS TO USE PROCEEDS FROM LOAN TO PROVIDE WORKING CAPITAL TO FUND ONGOING OPS AND TO SUPPORT CLINICAL TRIALS; 20/04/2018 - DJ CytoSorbents Corporation, Inst Holders, 1Q 2018 (CTSO); 23/03/2018 - CytoSorbents Access Event Set By LifeSci Advisors for Mar. 28; 04/05/2018 - New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security, Washington Re

Borgwarner Inc (BWA) investors sentiment increased to 1.13 in Q2 2019. It’s up 0.06, from 1.07 in 2019Q1. The ratio has improved, as 193 active investment managers increased and opened new positions, while 171 trimmed and sold positions in Borgwarner Inc. The active investment managers in our database now own: 181.04 million shares, up from 180.66 million shares in 2019Q1. Also, the number of active investment managers holding Borgwarner Inc in top ten positions decreased from 6 to 3 for a decrease of 3. Sold All: 37 Reduced: 134 Increased: 136 New Position: 57.

Analysts await BorgWarner Inc. (NYSE:BWA) to report earnings on October, 24. They expect $0.87 EPS, down 13.00% or $0.13 from last year’s $1 per share. BWA’s profit will be $179.67M for 10.32 P/E if the $0.87 EPS becomes a reality. After $1.00 actual EPS reported by BorgWarner Inc. for the previous quarter, Wall Street now forecasts -13.00% negative EPS growth.

More notable recent BorgWarner Inc. (NYSE:BWA) news were published by: Finance.Yahoo.com which released: “BorgWarner Inc. (NYSE:BWA): Has Recent Earnings Growth Beaten Long-Term Trend? - Yahoo Finance” on September 09, 2019, also Prnewswire.com with their article: “BorgWarner Celebrates Production of 70 Million Starters in South Korea - PRNewswire” published on October 01, 2019, Fool.com published: “Here’s Why BorgWarner Stock Crashed in August - Motley Fool” on September 04, 2019. More interesting news about BorgWarner Inc. (NYSE:BWA) were released by: Prnewswire.com and their article: “Webcast Alert: BorgWarner 2019 Third Quarter Results Conference Call - PRNewswire” published on September 18, 2019 as well as Finance.Yahoo.com‘s news article titled: “Should You Buy BorgWarner Inc. (NYSE:BWA) For Its Dividend? - Yahoo Finance” with publication date: August 17, 2019.

BorgWarner Inc. provides solutions for combustion, hybrid, and electric vehicles worldwide. The company has market cap of $7.42 billion. The firm operates through two divisions, Engine and Drivetrain. It has a 9.76 P/E ratio. The Engine segment develops and makes turbochargers; and timing systems, such as timing chains, variable cam timing products, crankshaft and camshaft sprockets, tensioners, guides and snubbers, HY-VO front-wheel drive transmission chains, and four-wheel drive chains for light vehicles.

Black Creek Investment Management Inc. holds 8.79% of its portfolio in BorgWarner Inc. for 6.35 million shares. Turtle Creek Asset Management Inc. owns 2.31 million shares or 7.29% of their US portfolio. Moreover, Minneapolis Portfolio Management Group Llc has 4.08% invested in the company for 818,772 shares. The Ohio-based Diamond Hill Capital Management Inc has invested 2.24% in the stock. Euclidean Technologies Management Llc, a New York-based fund reported 53,490 shares.

The stock decreased 2.04% or $0.75 during the last trading session, reaching $35.93. About 1.38M shares traded. BorgWarner Inc. (BWA) has declined 17.03% since October 1, 2018 and is downtrending. It has underperformed by 17.03% the S&P500. Some Historical BWA News: 08/03/2018 - Grand Opening: BorgWarner Inaugurates Latest Turbocharger Production Facility in Thailand; 26/04/2018 - BORGWARNER INC - 2018 NET EARNINGS ARE NOW EXPECTED TO BE WITHIN A RANGE OF $4.30 TO $4.40; 26/04/2018 - BORGWARNER INC BWA.N SEES FY 2018 SALES $10.77 BLN TO $10.94 BLN; 18/05/2018 - 2018 Louis Schwitzer Award Recognizes Engineers on Track for Success; 26/04/2018 - BorgWarner Sees 2Q EPS $1.09-EPS $1.11; 21/05/2018 - BorgWarner to Host Investor Day on September 18, 2018; 26/04/2018 - BORGWARNER INC - EXPECTS SECOND QUARTER 2018 ORGANIC NET SALES GROWTH OF 7.0% TO 9.0%; 02/05/2018 - BorgWarner Chief Legal Officer John J. Gasparovic Retires; 22/03/2018 - BORGWARNER INC BWA.N : MORGAN STANLEY RAISES TO OVERWEIGHT FROM UNDERWEIGHT; 26/04/2018 - BorgWarner Declares Quarterly Dividend

Since August 16, 2019, it had 1 buying transaction, and 0 insider sales for $31,395 activity. On Friday, August 16 the insider BLOCH KATHLEEN P. bought $31,395.

More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Finance.Yahoo.com which released: “Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) - Yahoo Finance” on September 21, 2019, also Prnewswire.com with their article: “CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock - PRNewswire” published on September 25, 2019, Prnewswire.com published: “CytoSorbents to Present at the HC Wainwright 21st Annual Global Investment Conference - PRNewswire” on September 09, 2019. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis - PRNewswire” published on September 13, 2019 as well as Prnewswire.com‘s news article titled: “First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence - PRNewswire” with publication date: September 16, 2019.

Investors sentiment decreased to 1.29 in Q2 2019. Its down 0.07, from 1.36 in 2019Q1. It worsened, as 7 investors sold Cytosorbents Corporation shares while 17 reduced holdings. 11 funds opened positions while 20 raised stakes. 7.96 million shares or 1.03% less from 8.04 million shares in 2019Q1 were reported. Manufacturers Life Insurance The stated it has 0% in Cytosorbents Corporation (NASDAQ:CTSO). Rhumbline Advisers reported 0% stake. Bradley Foster & Sargent Ct has 0.03% invested in Cytosorbents Corporation (NASDAQ:CTSO). Bnp Paribas Arbitrage Sa reported 3,392 shares. Group invested in 0% or 19,468 shares. Deutsche Savings Bank Ag stated it has 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Ny State Common Retirement Fund, a New York-based fund reported 17,600 shares. Credit Suisse Ag accumulated 15,751 shares. D E Shaw & Com has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO). Granite Inv Prtn Llc reported 0.01% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Nebraska-based Ameritas Invest Ptnrs has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). United Kingdom-based Legal General Group Public Ltd Company has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). State Bank Of America Corporation De holds 0% or 77,387 shares in its portfolio. Wells Fargo And Com Mn owns 25,213 shares. Citigroup Inc holds 8,577 shares or 0% of its portfolio.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $150.53 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

BorgWarner Inc. (NYSE:BWA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.